Anti-BCMA antibodies and uses thereof

US10072088B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Kodandaram Pillarisetti · Spring House, US
• Eric T. Baldwin · Carmel, US
• Gordon Powers · Malvern, US
• Rosa Maria Fernandes Cardoso · Spring House, US
• Ricardo Attar · Lawrenceville, US
• Francois Gaudet · Princeton, US

Key dates

• Filing date: Aug 16, 2016
• Grant date: Sep 11, 2018
• Expiry date: Aug 16, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD3 described herein.